ASCORBIC ACID- ascorbic acid injection, solution
Mylan Institutional LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

ASCORBIC ACID
Injection, USP

FOR INTRAVENOUS, INTRAMUSCULAR OR SUBCUTANEOUS USE.
CONTAINS NO PRESERVATIVES.

DESCRIPTION
Ascorbic Acid (vitamin C) is a water-soluble vitamin. It occurs as a white or slightly yellow crystal or powder with a light acidic taste. It is an antiscorbutic product. On exposure to air and light it gradually darkens. In the dry state it is reasonably stable in air, but in solution it rapidly oxidizes. Ascorbic Acid is freely soluble in water; sparingly soluble in alcohol; insoluble in chloroform, ether, and benzene.

The chemical name of Ascorbic Acid is L-ascorbic acid. The molecular formula is C\textsubscript{6}H\textsubscript{8}O\textsubscript{6} and the molecular weight is 176.13. The structural formula is as follows:

![Structural formula of Ascorbic Acid](image)

Ascorbic Acid injection is a clear, colorless to slightly yellow sterile solution of Ascorbic Acid in Water for Injection, for intravenous, intramuscular or subcutaneous use. Each ml contains: Ascorbic Acid 500 mg, Disodium Edetate 0.25 mg, Sodium Hydroxide 110 mg, in Water for Injection q.s. pH (range 5.5 to 7.0) adjusted with Sodium Bicarbonate and Sodium Hydroxide. Contains no preservatives.

CLINICAL PHARMACOLOGY
In humans, an exogenous source of ascorbic acid is required for collagen formulation and tissue repair. Ascorbic acid is reversibly oxidized to dehydroascorbic acid in the body. These two forms of the vitamin are believed to be important in oxidation-reduction reactions. The vitamin is involved in tyrosine metabolism, conversion of folic acid to folinic acid, carbohydrate metabolism, synthesis of lipids and proteins, iron metabolism, resistance to infections, and cellular respiration.

Ascorbic acid deficiency results in scurvy. Collagenous structures are primarily affected, lesions develop in bones and blood vessels. Administration of ascorbic acid completely reverses the symptoms of ascorbic acid deficiency.

INDICATIONS AND USAGE
Ascorbic acid is recommended for the prevention and treatment of scurvy. Its parenteral administration is desirable for patients with an acute deficiency or for those whose absorption of orally ingested ascorbic acid is uncertain.

Symptoms of mild deficiency may include faulty bone and tooth development, gingivitis, bleeding gums, and loosened teeth. Febrile states, chronic illness, and infection (pneumonia, whooping cough, tuberculosis, diphtheria, sinusitis, rheumatic fever, etc.) increases the need for ascorbic acid.

Hemovascular disorders, burns, delayed fracture and wound healing are indications for an increase in the daily intake.

CONTRAINDICATIONS
There are no contraindications to the administration of ascorbic acid.

WARNINGS
Diabetics, patients prone to recurrent renal calculi, those undergoing stool occult blood tests and those on sodium restricted diets or anticoagulant therapy should not take excessive doses of ascorbic acid over an extended period of time.

PRECAUTIONS

General Precautions
Too-rapid intravenous injection is to be avoided.

Laboratory Tests
Diabetics taking more than 500 mg of ascorbic acid daily, may obtain false reading of the urinary glucose test. No exogenous ascorbic acid should be ingested for 48 to 72 hours before amine dependent stool occult blood tests are conducted because possible false negative results may occur.

Drug Interactions
Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.

Usage in Pregnancy

Pregnancy Category C
Animal reproduction studies have not been conducted with Ascorbic Acid Injection. It is also not known whether Ascorbic Acid Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ascorbic Acid Injection should be given to a pregnant woman only if clearly needed.

Nursing Mothers
Caution should be exercised when Ascorbic Acid Injection is administered to a nursing woman.

ADVERSE REACTIONS
Transient mild soreness may occur at the site of intramuscular or subcutaneous injection. Too-rapid intravenous administration of the solution may cause temporary faintness or dizziness.

DOSAGE AND ADMINISTRATION
Ascorbic acid is usually administered orally. When oral administration is not feasible or when malabsorption is suspected, the drug may be administered intramuscularly, intravenously or subcutaneously. When given parenterally, utilization of the vitamin reportedly is best after IM administration, which is the preferred parenteral route.

For intravenous injection, dilution into a large volume parenteral such as Normal Saline or Glucose is recommended to minimize the adverse reactions associated with intravenous injection.

The average protective dose of ascorbic acid for adults is 70 to 150 mg daily. In the presence of scurvy, doses of 300 mg to 1 gram daily are recommended. However, as much as 6 grams have been administered parenterally to normal adults without evidence of toxicity.

To enhance wound-healing, doses of 300 to 500 mg daily for a week to ten days, both preoperatively and postoperatively, are generally considered adequate, although considerably larger amounts have been recommended. In the treatment of burns, doses are governed by the extent of tissue injury. For severe burns, daily doses of 1 to 2 grams are recommended. In other conditions in which the need for ascorbic acid is increased, three to five times the daily optimum allowances appear to be adequate.

**WARNING**

PRESSURE MAY DEVELOP WITHIN THE VIAL UPON STORAGE.

Exercise care when withdrawing and/or relieve pressure by first inserting sterile empty syringe into vial thus allowing pressure to equilibrate.

When using dispensing vials use aseptic technique. Dispense entire contents in aliquots under a laminar flow hood without delay or within 4 hours after entry or discard remaining content after first withdrawal. Prepare stoppers with a suitable antiseptic solution. Do not use unless solution is clear and seal is intact.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

**HOW SUPPLIED**

Ascorbic Acid for Injection USP, 500 mg/mL, is available in:

**Mylan Institutional LLC**

NDC 67457-118-50

carton containing a 50 mL sterile dispensing vial, individually packaged

**NOVAPLUS®**

NDC 67457-303-50

carton containing a 50 mL sterile dispensing vial, individually packaged

**PROTECT FROM LIGHT. STORE IN CARTON UNTIL TIME OF USE.** Store between 2° to 8°C (36° to 46°F).

Manufactured for:

**Mylan Institutional LLC**

Rockford, IL 61103 U.S.A.

Manufactured by:

**Mylan Institutional**

Galway, Ireland

0316L107
PRINCIPAL DISPLAY PANEL - 50 mL Carton

NDC 67457-118-50     50 mL

Ascorbic Acid Injection, USP 500 mg/mL
For Intravenous, Intramuscular or Subcutaneous Use
Rx only   Vial

STORE BETWEEN 2° TO 8°C (36° TO 46°F).
Store in carton until time of use.

PROTECT FROM LIGHT.

PRESSURE MAY DEVELOP UPON STORAGE. EXERCISE CARE WHEN WITHDRAWING.

Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.

Manufactured by:
Mylan Institutional
Galway, Ireland

Mylan.com

Each mL contains: Ascorbic Acid 500 mg, Disodium Edetate 0.25 mg, Sodium Hydroxide 110 mg, in Water for Injection q.s. pH (range 5.5 to 7.0) adjusted with Sodium Bicarbonate and Sodium Hydroxide.

Contains no preservatives.

USUAL ADULT DOSAGE: See accompanying prescribing information.

WARNING: Use aseptic techniques. Dispense entire contents in aliquots under a laminar flow hood without delay or within 4 hours after entry, or discard remaining contents after first withdrawal. Prepare stoppers with a suitable antiseptic solution.

Do not use unless solution is clear and seal is intact.
MI:118:1C:R2

PRINCIPAL DISPLAY PANEL - 50 mL Carton
NDC 67457-303-50   Rx only
Ascorbic
Acid
Injection, USP
For Intravenous, Intramuscular or Subcutaneous Use
500 mg per mL
Novation and NOVAPLUS are registered trademarks
of Novation, LLC.

STORE BETWEEN 2° TO 8°C (36° TO 46°F).

Store in carton until time of use.

PROTECT FROM LIGHT.

PRESSURE MAY DEVELOP UPON STORAGE. EXERCISE CARE WHEN WITHDRAWING.

Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.

Manufactured by:
Mylan Institutional
Galway, Ireland

MI:303:1C:R1

Each mL contains: Ascorbic Acid 500 mg, Disodium Edetate 0.25 mg, Sodium Hydroxide 110 mg, in Water for Injection q.s. pH (range 5.5 to 7.0) adjusted with Sodium Bicarbonate and Sodium Hydroxide.

Contains no preservatives.

USUAL ADULT DOSAGE: See accompanying prescribing information.

WARNING: Use aseptic techniques. Dispense entire contents in aliquots under a laminar flow hood without delay or within 4 hours after entry, or discard remaining contents after first withdrawal. Prepare stoppers with a suitable antiseptic solution.

Do not use unless solution is clear and seal is intact.
ASCORBIC ACID
ascorbic acid injection, solution

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC: 67457-118</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>DEA Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS</td>
<td></td>
</tr>
</tbody>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbic Acid</td>
<td>Ascorbic Acid</td>
<td>500 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edetate Disodium (UNII: 7FLD91C86K)</td>
<td>0.25 mg in 1 mL</td>
</tr>
<tr>
<td>Sodium Hydioxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Sodium Bicarbonate (UNII: 8MDF5V39QO)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:67457-118-50</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>50 mL in 1 VIAL, GLASS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unapproved drug other</td>
<td></td>
<td>06/01/1999</td>
<td></td>
</tr>
</tbody>
</table>

### ASCORBIC ACID

ascorbic acid injection, solution

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Route of Administration</th>
<th>Item Code (Source)</th>
<th>DEA Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS</td>
<td>NDC:67457-303</td>
<td></td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edetate Disodium (UNII: 7FLD91C86K)</td>
<td>0.25 mg in 1 mL</td>
</tr>
<tr>
<td>Sodium Hydioxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Sodium Bicarbonate (UNII: 8MDF5V39QO)</td>
<td></td>
</tr>
</tbody>
</table>
### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:67457-303-50</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>50 mL in 1 VIAL, GLASS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unapproved drug other</td>
<td></td>
<td>06/01/1999</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Mylan Institutional LLC (790384502)

Revised: 2/2010